daiichi sankyo co ltd (DSKYF:OTC US)
daiichi sankyo co ltd (DSKYF) Snapshot
|
Open
$18.50
|
Previous Close
$18.50
|
|
|
Day High
$18.50
|
Day Low
$18.50
|
|
|
52 Week High
03/22/13 - $19.63
|
52 Week Low
11/16/12 - $14.83
|
|
|
Market Cap
--
|
Average Volume 10 Days
470.0
|
|
|
EPS TTM
--
|
Shares Outstanding
0.0
|
|
|
EX-Date
09/26/13
|
P/E TM
--
|
|
|
Dividend
$59.56
|
Dividend Yield
3.80%
|
daiichi sankyo co ltd (DSKYF) Latest News
daiichi sankyo co ltd (DSKYF) Related Businessweek News
No Related Businessweek News Founddaiichi sankyo co ltd (DSKYF) Details
Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products. It offers various products for the treatment of basic ailments, such as hypertension, hyperlipidemia, and diabetes, as well as products for the treatment of cardiovascular events, including heart failure, arrhythmia, and heart attack. The company is also involved in consumer health operations consisting of functional foods and skin care products. In addition, it develops products for the treatment of cardiovascular diseases, glucose metabolic disorders, infectious diseases, cancer, immunity and allergies, and bone/joint diseases. Further, the company manufactures and sells over-the-counter drugs, cosmetics, medical equipment, food, beverages, veterinary medicines, and active pharmaceutical ingredients and intermediates; and engages in the research, development, manufacture, and sale of vaccines, as well as provision of agency services for pharmaceuticals. It primarily operates in Japan, North America, Europe, South and Central America, and Asia. The company was founded in 2005 and is headquartered in Tokyo, Japan.
daiichi sankyo co ltd (DSKYF) Key Developments
Daiichi Sankyo Company, Limited reported consolidated earnings results for the fiscal year ended March 31, 2013. For the year, the company reported net sales of JPY 997,852 million, operating income of JPY 100,516 million, ordinary income of JPY 99,147 million, net income of JPY 66,621 million or JPY 94.64 per share against net sales of JPY 923,677 million, operating income of JPY 98,202 million, ordinary income of JPY 76,217 million, net income of JPY 10,383 million or JPY 14.75 per share of previous year. Net income was 33.2% higher than its previous forecast. This was the result of a higher income before income taxes due to a gain on sales of investment securities, greater deferred tax assets related to unrealized gains from inventories, and the significant lowering of the income tax rate due to the expansion of tax deductions related to clinical trial and research costs.
Daiichi Sankyo Company, Limited, 2013 Earnings Call, May 14, 2013
Daiichi Sankyo Company, Limited announced that they will report fiscal year 2013 results at 1:00 PM, Tokyo Standard Time on May 13, 2013
| Recently Viewed | |||
| DSKYF:US | $18.50 USD | 0.00 |  |
| Company | Last | Change |
| Astex Pharmaceuticals | $5.36 USD | +0.24 |
| Beiersdorf AG | €70.54 EUR | +0.19 |
| BioCryst Pharmaceuticals Inc | $1.60 USD | -0.06 |
| Cyclacel Pharmaceuticals Inc | $3.26 USD | +0.075 |
| Eisai Co Ltd | ¥4,185 JPY | +5.00 |
| View Industry Companies | ||
Industry Analysis
DSKYF
Industry Average
| Valuation | DSKYF | Industry Range |
| Price/Earnings | 18.0x |
|
| Price/Sales | 1.2x |
|
| Price/Book | 1.3x |
|
| Price/Cash Flow | 18.1x |
|
| TEV/Sales | 0.5x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact DAIICHI SANKYO CO LTD, please visit www.daiichisankyo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
